Company Overview: NVO

Upcoming Projects (NVO)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (NVO)

Exploring the hemophilia landscape with a particular focus on CBIO's CB2679d and Marzeptacog Alfa (MarzAA)
Tickers: CBIO, NVO, SNY, BIVV, CSL.AX
Executed On: May 08, 2018 at 03:00 PM EDT
The market potential of a likely soon to be approved Afrezza. Will this launch be different (better) than Exubera?
Tickers: MNKD, NVO, PFE, LLY
Executed On: Apr 15, 2014 at 01:00 PM EDT

Expired Projects (NVO)

Discussing the Landscape of the Injectable Long-Acting Insulin Market for Merck's Glargine (MK-1293) in Type 1 & 2 Diabetes Following Expected April PDUFA
Tickers: MRK, SNY, LLY, NVO
Execute By: Apr 14, 2017
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
Understanding the potential of Novo Nordisk's (NVO) Tresiba in treatment of type 2 diabetes
Ticker: NVO
Execute By: Feb 05, 2016

Upcoming & Overdue Catalysts (NVO)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (NVO)

PDUFA for Novo Nordisk's (NVO) N8-GP in Hemophilia A expected February 26, 2019.
Ticker: NVO
Occurred on: Feb 19, 2019
Post hoc subgroup analyses released of the Phase 3 MACE and SUSTAIN 6 studies evaluating Novo Nordisk's (NVO) OZEMPIC (semaglutide) in type 2 diabetics with high CV risk
Ticker: NVO
Occurred on: Aug 26, 2018
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017
CHMP Recommends Addition of SWITCH 1 and SWITCH 2 Data to Novo's (NVO) Tresiba
Ticker: NVO
Occurred on: Mar 24, 2017
CHMP Recommends Novo's (NVO) Refixia for Approval in Hemophilia B
Ticker: NVO
Occurred on: Mar 24, 2017
European Commission Approves Novo's (NVO) Fast Acting Insulin Fiasp
Ticker: NVO
Occurred on: Jan 10, 2017
Novo Nordisk expects to file semaglutide for regulatory review in the US and EU in the fourth quarter of 2016
Ticker: NVO
Occurred on: Dec 05, 2016
Novo Nordisk (NVO) receives US FDA approval for Xultophy 100/3.6
Ticker: NVO
Occurred on: Nov 21, 2016
Novo Nordisk's (NVO) Fiasp (Fast-Acting Insulin Aspart) in Type 1 and Type 2 Diabetes Granted Positive Opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)
Ticker: NVO
Occurred on: Nov 14, 2016
Novartis's (NVO) Midostaurin (PKC412) Granted Priority Review by FDA for Acute Myeloid Leukemia (AML) and Mastocytosis
Ticker: NVO
Occurred on: Nov 14, 2016
Novo Nordisk (NVO) Submits Type 2 Variation Application to EMA to Add Data from Two Late-Stage Studies to Label for Long-Acting Diabetes Med Tresiba
Ticker: NVO
Occurred on: Nov 10, 2016
Novo Nordisk's (NVO) NDA for Faster-Acting Insulin Rejected by FDA
Ticker: NVO
Occurred on: Oct 11, 2016
Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba label
Ticker: NVO
Occurred on: Sep 23, 2016
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Ticker: NVO
Occurred on: May 24, 2016
Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial
Ticker: NVO
Occurred on: Apr 28, 2016
Victoza significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
Ticker: NVO
Occurred on: Mar 04, 2016
Novo Nordisk (NVO) Expects to Release Data from SWITCH-1 Trial Evaluating Tresiba in Type 1 Diabetes Patients in Q1 2016
Ticker: NVO
Occurred on: Feb 23, 2016
Tresiba demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes
Ticker: NVO
Occurred on: Feb 23, 2016
Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes
Ticker: NVO
Occurred on: Feb 23, 2016
Tresiba demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes; headline results of SWITCH 1 expected later in the first quarter of 2016
Ticker: NVO
Occurred on: Jan 29, 2016
Top-line Phase 3b Data Released From Novo Nordisk's (NVO) SWITCH-2 Trial Evaluating Tresiba Versus Insulin Glargine in Type 2 Diabetes Patients
Ticker: NVO
Occurred on: Jan 29, 2016

Strategic Initiatives (NVO)

Novo Nordisk (NVO) Submits Supplemental New Drug Application in U.S and Canada to Include the Cardiovascular Outcomes on Labels From LEADER Study for Victoza in Type 2 diabetes
Ticker: NVO
Announcement Date: Oct 26, 2016

NVO Overview